Back to News
Market Impact: 0.35
Galderma Reports Positive Topline Results For Restylane Volyme In Temple Hollowing Study
Source: Nasdaq
Healthcare & BiotechProduct Launches
Galderma reported positive topline results for Restylane Volyme in a study targeting moderate-to-severe temple hollowing. The study met its primary endpoint, supporting the product's efficacy profile and potentially expanding Galderma's aesthetics-market opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
GALD0.72
More News
- DeepSeek Drops Enhanced Coding Agent With Aim to Rival Anthropic
- Backbone of a beast – charting Nvidia's rise to networking titan
- The rise of the 15-foot skeleton—how a viral novelty became a Halloween staple
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Bolt Graphics powers on its first Zeus GPU
- Swiss firms plan to expand China investments as trade deal deepens ties